Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
-
EMA approval · 2026-02-05EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH
EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …
-
EMA approval · 2026-01-30EMA Authorised: Pemetrexed Accord (pemetrexed disodium hemipentahydrate) — Accord Healthcare S.L.U.
EMA authorised Pemetrexed Accord (pemetrexed disodium hemipentahydrate) for treatment of non-small cell lung cancer and mesothelioma; market…
-
EMA approval · 2026-01-29EMA Authorised: Zykadia (ceritinib) — Novartis Europharm Limited
The European Medicines Agency authorised Zykadia (ceritinib) for the treatment of non-small cell lung cancer. The marketing authorization ho…
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-28EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG
EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…
-
EMA approval · 2026-01-27EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC
EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma,…
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
EMA approval · 2026-01-26EMA Authorised: Tevimbra (tislelizumab) — Beone Medicines Ireland Limited
EMA authorised Tevimbra (tislelizumab) from Beone Medicines Ireland Limited for multiple cancer indications, including esophageal squamous c…
-
EMA approval · 2026-01-21EMA Authorised: Abraxane (paclitaxel) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Abraxane (paclitaxel) by Bristol-Myers Squibb Pharma EEIG for breast cancer, pancreatic cancer, and non-small cell lung cance…
-
EMA approval · 2026-01-19EMA Authorised: Tagrisso (osimertinib mesilate) — AstraZeneca AB
The European Medicines Agency authorised Tagrisso (osimertinib mesilate) for use in non-small cell lung cancer.
-
EMA approval · 2026-01-16EMA Authorised: Alimta (pemetrexed) — Eli Lilly Nederland B.V.
EMA has authorised the marketing of Alimta (pemetrexed) for malignant mesothelioma and non-small cell lung cancer in the EU. The marketing a…
-
EMA approval · 2026-01-15EMA Authorised: Pemetrexed Pfizer (previously Pemetrexed Hospira) (pemetrexed disodium;pemetrexed disodium hemipentahydrate) — Pfizer Europe MA EEIG
The European Medicines Agency authorised a pemetrexed disodium product marketed as Pemetrexed Pfizer (formerly Pemetrexed Hospira) for non-s…
-
FDA approval · 2026-01-08FDA Approved: ENSACOVE — Supplemental Application (Xcovery Holdings, Inc.)
FDA approved ENSACOVE's supplemental application for ensartinib submitted by Xcovery Holdings, Inc.
-
EMA approval · 2026-01-08EMA Authorised: Xalkori (crizotinib) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Xalkori (crizotinib) for non-small cell lung cancer with Pfizer Europe MA EEIG as the marketing aut…
-
FDA approval · 2025-12-17FDA Approved: RYBREVANT FASPRO — Original Application (Janssen Biotech, Inc.)
FDA approved Rybrevant FASPRO, a subcutaneous co-formulation of amivantamab and hyaluronidase-lpuj, under an original application by Janssen…
-
EMA approval · 2025-12-02EMA Authorised: Krazati (adagrasib) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Krazati (adagrasib) for non-small cell lung cancer under conditional approval.
-
EMA approval · 2025-11-21EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Yervoy (ipilimumab) for multiple cancer indications. It lists melanoma, renal cell carcinoma, non-s…
-
FDA approval · 2025-11-20FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for RETEVMO (selpercatinib) submitted by Eli Lilly and Company, expanding its approved indicatio…
-
FDA approval · 2025-11-07FDA Approved: LAZCLUZE — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for LazCLUZE (lazertinib) from Janssen Biotech, Inc.
-
EMA approval · 2025-10-29EMA Authorised: Rybrevant (amivantamab) — Janssen-Cilag International N.V.
EMA authorised Rybrevant (amivantamab) for non-small cell lung cancer. The marketing authorization holder is Janssen-Cilag International N.V…
-
FDA approval · 2025-10-09FDA Approved: PEMETREXED — Supplemental Application (Waverley Pharma Inc)
FDA approved a supplemental application for pemetrexed disodium by Waverley Pharma Inc, resulting in updated approval/label for the generic …
-
EMA approval · 2025-08-27EMA Authorised: Tabrecta (capmatinib dihydrochloride monohydrate) — Novartis Europharm Limited
The EMA authorised Tabrecta (capmatinib dihydrochloride monohydrate) for non-small cell lung cancer. Novartis Europharm Limited is the marke…